Literature DB >> 21187491

Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors.

Masoumeh Ghayouri1, David Boulware, Aejaz Nasir, Jonathan Strosberg, Larry Kvols, Domenico Coppola.   

Abstract

BACKGROUND: Akt is a regulator of cell proliferation, tumorigenesis and apoptosis. This study evaluated the incidence of Akt activation in a subset of neuroendocrine tumors (NETs) and its correlation to clinical pathological parameters.
MATERIALS AND METHODS: A subset of 46 samples from patients with enteropancreatic NETs (26 male and 20 female) were selected for evaluation. The tissue slides were stained with a mouse monoclonal antiphospho-Akt antibody using the avidin-biotin-complex method.
RESULTS: The tumors were from the small (n = 18) and large bowel (n = 9) and from the pancreas (n = 16). Activation of Akt was detected in 61% (28/46) of cases. No statistical correlation was found between the p-Akt score and tumor grade (p = 0.72), tumor size (p = 0.72) and the presence of metastases (p = 0.52).
CONCLUSION: This study shows activation of Akt in a subset of enteropancreatic NET for the first time. This finding suggests a role of p-Akt in NET carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187491

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.

Authors:  Marco Gallo; Pasqualino Malandrino; Giuseppe Fanciulli; Francesca Rota; Antongiulio Faggiano; Annamaria Colao
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

2.  Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.

Authors:  Rony A François; Kyungah Maeng; Akbar Nawab; Frederic J Kaye; Steven N Hochwald; Maria Zajac-Kaye
Journal:  J Natl Cancer Inst       Date:  2015-05-12       Impact factor: 13.506

Review 3.  Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Authors:  P Gajate; T Alonso-Gordoa; O Martínez-Sáez; J Molina-Cerrillo; E Grande
Journal:  Clin Transl Oncol       Date:  2017-11-09       Impact factor: 3.405

Review 4.  Profiling mTOR pathway in neuroendocrine tumors.

Authors:  S Cingarlini; M Bonomi; V Corbo; A Scarpa; G Tortora
Journal:  Target Oncol       Date:  2012-08-14       Impact factor: 4.493

Review 5.  Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Authors:  Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2021-10-12       Impact factor: 6.639

Review 6.  Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Authors:  Jianliang Zhang; Rony Francois; Renuka Iyer; Mukund Seshadri; Maria Zajac-Kaye; Steven N Hochwald
Journal:  J Natl Cancer Inst       Date:  2013-07-09       Impact factor: 13.506

Review 7.  The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.

Authors:  Alexandria T Phan; Bhuvanesh Dave
Journal:  Cancer Med       Date:  2016-08-18       Impact factor: 4.452

8.  Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

Authors:  Rossana Berardi; Mariangela Torniai; Sara Pusceddu; Francesca Spada; Toni Ibrahim; Maria Pia Brizzi; Lorenzo Antonuzzo; Piero Ferolla; Francesco Panzuto; Nicola Silvestris; Stefano Partelli; Benedetta Ferretti; Federica Freddari; Calogero Gucciardino; Enrica Testa; Laura Concas; Sabina Murgioni; Alberto Bongiovanni; Clizia Zichi; Nada Riva; Maria Rinzivillo; Oronzo Brunetti; Lucio Giustini; Francesco Di Costanzo; Gianfranco Delle Fave; Nicola Fazio; Filippo De Braud; Massimo Falconi; Stefano Cascinu
Journal:  Cancer Med       Date:  2017-05-25       Impact factor: 4.452

Review 9.  PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franziska Briest; Patricia Grabowski
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

Review 10.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues.

Authors:  Helen Louise Robbins; Angela Hague
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.